iifl-logo-icon 1

Ind-Swift Laboratories Ltd Share Price

102.71
(-1.24%)
Nov 21, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open104
  • Day's High104
  • 52 Wk High186
  • Prev. Close104
  • Day's Low102
  • 52 Wk Low 89.5
  • Turnover (lac)15.39
  • P/E5.75
  • Face Value10
  • Book Value157.18
  • EPS18.06
  • Mkt. Cap (Cr.)606.88
  • Div. Yield0
View All Historical Data
No Records Found

Ind-Swift Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

104

Prev. Close

104

Turnover(Lac.)

15.39

Day's High

104

Day's Low

102

52 Week's High

186

52 Week's Low

89.5

Book Value

157.18

Face Value

10

Mkt Cap (₹ Cr.)

606.88

P/E

5.75

EPS

18.06

Divi. Yield

0

Ind-Swift Laboratories Ltd Corporate Action

28 Jun 2024

12:00 AM

EGM

arrow

6 Nov 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

14 Aug 2024

12:00 AM

BookCloser

arrow

2 Sep 2024

12:00 AM

AGM

Announcement Date: 02 Sep, 2024

arrow

Ind-Swift Laboratories Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ind-Swift Laboratories Ltd SHAREHOLDING SNAPSHOT

24 Nov, 2024|10:29 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 42.00%

Foreign: 0.00%

Indian: 42.00%

Non-Promoter- 1.59%

Institutions: 1.58%

Non-Institutions: 56.40%

Custodian: 0.00%

Share Price

Ind-Swift Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

59.09

59.81

59.81

59.81

Preference Capital

0

0

0

0

Reserves

863.16

615.54

572.75

578.89

Net Worth

922.25

675.35

632.56

638.7

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

856.57

751.83

731.29

693.71

yoy growth (%)

13.93

2.8

5.41

8.6

Raw materials

-424.99

-378.84

-375.06

-395.81

As % of sales

49.61

50.38

51.28

57.05

Employee costs

-104.16

-100.37

-89.3

-71.61

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

16.11

-19.56

30.51

-50.85

Depreciation

-87.29

-90.05

-86.61

-88.25

Tax paid

-20.51

-1.22

-10.95

16.46

Working capital

24.4

224.01

-12.39

-206.93

Other operating items

View Cash Flow
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

13.93

2.8

5.41

8.6

Op profit growth

27.14

11.71

20.97

-3.11

EBIT growth

32.31

49.44

56.9

-0.94

Net profit growth

-78.84

-217.94

-144.36

-32.51

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,280.9

1,207.31

1,038.73

891.34

779.64

Excise Duty

0

0

0

0

0

Net Sales

1,280.9

1,207.31

1,038.73

891.34

779.64

Other Operating Income

0

0

0

0

0

Other Income

431.96

33.5

43.5

22.7

33.4

Ind-Swift Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,795.3

154.714,26,517.78863.290.765,123.6798.33

Divis Laboratories Ltd

DIVISLAB

5,998.35

86.351,58,636.065180.52,302513.62

Cipla Ltd

CIPLA

1,486.5

27.951,18,365.231,178.160.893,969.86360.74

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,167.1

64.221,05,067.364600.92,376222.38

Mankind Pharma Ltd

MANKIND

2,551.6

51.021,02,273.02634.4302,529.74269.23

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ind-Swift Laboratories Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

N R Munjal

Joint Managing Director

Himanshu Jain

Company Sec. & Compli. Officer

Pradeep Verma

Executive Director

Rishav Mehta

Independent Director

S P Sharma

Independent Director

Neerja Chathley

Independent Director

Ashwani K Vig

Executive Director

Sahil Munjal

Independent Director

Rajendra Kumar Gupta

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA.Ind-Swift Laboratories Ltd was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they enter
Read More

Company FAQs

What is the Ind-Swift Laboratories Ltd share price today?

The Ind-Swift Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹102.71 today.

What is the Market Cap of Ind-Swift Laboratories Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ind-Swift Laboratories Ltd is ₹606.88 Cr. as of 21 Nov ‘24

What is the PE and PB ratio of Ind-Swift Laboratories Ltd?

The PE and PB ratios of Ind-Swift Laboratories Ltd is 5.75 and 0.61 as of 21 Nov ‘24

What is the 52 Week High and Low of Ind-Swift Laboratories Ltd?

The 52-week high/low is the highest and lowest price at which a Ind-Swift Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ind-Swift Laboratories Ltd is ₹89.5 and ₹186 as of 21 Nov ‘24

What is the CAGR of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd's CAGR for 5 Years at 30.49%, 3 Years at 13.44%, 1 Year at 11.04%, 6 Month at -5.12%, 3 Month at -22.19% and 1 Month at -17.94%.

What is the shareholding pattern of Ind-Swift Laboratories Ltd?

The shareholding pattern of Ind-Swift Laboratories Ltd is as follows:
Promoters - 42.00 %
Institutions - 1.59 %
Public - 56.41 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp